Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
0.9352
-0.0291 (-3.02%)
Jun 27, 2025, 4:00 PM - Market closed
Lineage Cell Therapeutics Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Lineage Cell Therapeutics stock ranges from a low of $2.00 to a high of $9.00. The average analyst price target of $4.20 forecasts a 349.10% increase in the stock price over the next year.
Price Target: $4.20 (+349.10%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Lineage Cell Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +113.86% | Jun 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +862.36% | Jun 23, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $4 → $3 | Strong Buy | Maintains | $4 → $3 | +220.79% | Mar 14, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +113.86% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +862.36% | Mar 11, 2025 |
Financial Forecast
Revenue This Year
8.26M
from 9.50M
Decreased by -13.02%
Revenue Next Year
27.48M
from 8.26M
Increased by 232.66%
EPS This Year
-0.09
from -0.09
EPS Next Year
-0.05
from -0.09
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.5M | 47.3M | 194.0M | ||
| Avg | 8.3M | 27.5M | 53.3M | ||
| Low | 2.9M | n/a | 4.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 63.6% | 471.9% | 605.7% | ||
| Avg | -13.0% | 232.7% | 94.0% | ||
| Low | -69.0% | - | -85.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.01 | 0.03 | -0.05 | ||
| Avg | -0.09 | -0.05 | -0.09 | ||
| Low | -0.15 | -0.15 | -0.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.